United States Patent 9,220,694 (Oil-in-Water Ophthalmic Emulsion): Scope, Claim Map, and US Patent Landscape
Executive summary: US 9,220,694 is an ophthalmic dry-eye formulation patent centered on an oil-in-water (O/W) emulsion with a tightly defined oil-phase selection (mineral oil and/or specific triglyceride oils), a specific cationic preservative system (cetalkonium chloride as the sole ammonium halide), and a defined low-dose surfactant band (0.1% to 1% w/w using tyloxapol and/or poloxamer 188). The independent claim is composition-focused but downstream claims broaden into gel dosage forms, positive zeta potential, nanoscale droplet sizing (100 to 500 nm), hypotonicity relative to normal tears, inclusion of tonicity and buffering excipients, and incorporation of an active principle (notably cyclosporine). For freedom-to-operate (FTO), the highest-risk elements are (i) “sole ammonium halide” requiring cetalkonium chloride exclusivity among ammonium halides, (ii) the specific surfactant family and concentration band, and (iii) droplet size and zeta potential parameters if asserted against formulation variants. For licensing strategy, claim 13+ and claim 14 create an active-agent bridge that can capture cyclosporine-containing products even where the formulation is positioned as a delivery system rather than a preservative system.
What is US Patent 9,220,694 and what problem does it claim to solve?
Answer (claim focus): The patent claims a dry-eye-relevant ophthalmic O/W emulsion designed around (1) a defined oil-phase and (2) specific excipient selections that drive emulsion stability and ocular compatibility: cetalkonium chloride as the sole ammonium halide preservative, tyloxapol/poloxamer 188 as surfactants in a specific range, with optional tonicity/buffer, hypotonicity, positive zeta potential, and nanoscale droplet size. It also claims cyclosporine-containing medicaments and kits.
High-level claim architecture
- Independent composition claim: Claim 1.
- Dependent narrowing claims: Specific oil definitions, mineral oil mixtures, addition of buffering/tonicity, tonicity agent selection (mannitol/glycerol), positive zeta potential, droplet size range, full exemplar composition combinations, hypotonicity vs normal tears, gel dosage form, toxicity comparison to an equivalent cetalkonium chloride solution, active principle inclusion.
- Active-agent dependent claims: Claim 14 specifies cyclosporine.
- Downstream product and method claims: Medicament (claim 15), medicament in gel form (claim 18), kit (claim 17), and preparation method for ophthalmic gel (claim 16).
What is the scope of independent claim 1 for the oil-in-water emulsion?
Answer (claim 1 core): An ophthalmic O/W emulsion with:
- Oil phase: mineral oil, castor oil, or medium chain triglycerides (MCTs).
- Ammonium halide: 0.0005% to 0.1% w/w of ammonium halide where cetalkonium chloride is the sole ammonium halide.
- Surfactant: 0.1% to 1% w/w surfactant selected from tyloxapol, poloxamer 188, or mixtures.
Claim 1 elements mapped to formulation variables
| Claim 1 element |
Claim language trigger |
Practical formulation variable |
Key infringement lever |
| Oil phase selection |
mineral oil OR castor oil OR MCT |
Choice of oil(s) in dispersed phase |
Using only different oil types can avoid literal coverage; mixing within listed oils keeps risk high |
| Preservative band + exclusivity |
0.0005% to 0.1% w/w ammonium halide; cetalkonium chloride sole ammonium halide |
Preservative identity and whether other ammonium halides are present |
Replacing cetalkonium chloride or adding other ammonium halides can reduce risk |
| Surfactant band + family constraint |
0.1% to 1% w/w tyloxapol/poloxamer 188/mixture |
Surfactant identity and total loading |
Substituting other surfactants outside this list likely avoids literal coverage; using tyloxapol/poloxamer in band captures |
Literal boundary conditions
- Concentration windows matter. The claim is not open-ended on either preservative or surfactant concentration.
- “Sole ammonium halide” is a hard gate. Even if total preservative is in-range, adding any additional ammonium halide besides cetalkonium chloride can defeat literal claim 1.
- O/W structure is required. A water-in-oil or microemulsion with different structural characterization can reduce literal risk, depending on claim construction and testing standards.
How do dependent claims 2-12 expand or narrow the emulsion scope?
Answer: Dependent claims refine oil identity, excipient sets, and performance attributes (zeta potential, droplet size, hypotonicity, gel suitability), increasing coverage for specific variants while tightening the exact parameter set.
Oil-phase refinements (claims 2, 8, 9)
- Claim 2: mineral oil can be a mixture of heavy and light mineral oil.
- Claim 8: exemplar combination: light and heavy mineral oil + tyloxapol + poloxamer 188 + mannitol + cetalkonium chloride.
- Claim 9: exemplar combination: light and heavy mineral oil + tyloxapol + poloxamer 188 + glycerol + cetalkonium chloride.
Scope impact: Claims 8 and 9 are strong “commercial embodiment” anchors, but they are narrower than claim 1. A product outside mannitol/glycerol selection may avoid these exemplars while still potentially falling under claim 3 (if tonicity is present generally) or claim 1 if tonicity is absent.
Buffers and tonicity (claims 3-5)
- Claim 3: emulsion further comprising buffering agents and/or at least one tonicity agent.
- Claim 4: tonicity agent is mannitol.
- Claim 5: tonicity agent is glycerol.
Scope impact: These claims expand beyond “just emulsion components” into typical ocular formulation space. If a product uses tonicity agents outside mannitol/glycerol, claim 4/5 are avoided but claim 3 could still be asserted if buffering agents and/or tonicity agents are present in general.
Surface charge and droplet size (claims 6-7)
- Claim 6: emulsion has positive zeta potential.
- Claim 7: droplet size 100 to 500 nm.
Scope impact: These are parameter claims. Even with correct excipient selection, failure to meet droplet size distribution or zeta potential sign can avoid these dependent claims, though claim 1 might still remain in play.
Hypotonicity (claim 10)
- Claim 10: emulsion is hypotonic relative to normal tears.
Scope impact: This parameter is often measurable (osmolality). Products formulated isotonic or hypertonic can avoid this dependent claim.
Dosage form and toxicity comparison (claims 11-12)
- Claim 11: emulsion in the form of a gel suitable for ophthalmic use.
- Claim 12: emulsion is less toxic than a solution containing the same amount of cetalkonium chloride by weight.
Scope impact: Claim 11 ties formulation to gel presentation. Claim 12 is a comparative safety claim; it can be leveraged in enforcement where biological data supports differentiation from solution-based preservative systems.
What does claim 13-14 do for active ingredients like cyclosporine?
Answer: The patent adds a delivery-system layer. Claim 13 states the emulsion can comprise an active principle. Claim 14 specifies cyclosporine.
Active-principle scope pathway
- Claim 13: “further comprising an active principle.”
- Claim 14: active principle is cyclosporine.
Scope impact for cyclosporine products:
- A cyclosporine ophthalmic product can be pulled into the claim set if it uses an emulsion that meets claim 1’s compositional gates (oil-phase selection, cetalkonium chloride as sole ammonium halide within 0.0005%–0.1% w/w, and tyloxapol/poloxamer 188 surfactants at 0.1%–1% w/w).
- Claim 14 itself is narrow in that it requires cyclosporine as the active principle but does not add new excipient constraints beyond claim 1.
What product claims (15-18) cover medicaments, gels, methods, and kits?
Answer: The patent includes direct medicament coverage, gel presentation, preparation method, and a kit configuration for dry eye treatment with cyclosporine emulsion(s).
Medicaments and gel forms (claims 15, 18)
- Claim 15: medicament comprising the emulsion of claim 1.
- Claim 18: medicament of claim 15 where the emulsion is in gel form suitable for ophthalmic use.
Scope impact: Even if the emulsion is made into different delivery formats, gel-specific protection exists via claim 18.
Method for preparing ophthalmic composition (claim 16)
- Claim 16: preparing the emulsion of claim 1 in a gel form for dry eye treatment.
Scope impact: Method claims can matter in manufacturing-based litigation where the commercial product’s formulation can be reverse engineered but process evidence may be more direct.
Kit claim (claim 17)
- Claim 17: kit for dry eye treatment comprising:
- a first emulsion of claim 1, and
- a second emulsion containing cyclosporine.
Scope impact: This is an enforcement hook for multi-component commercial packages and can capture competitive products that split actives or deliver cyclosporine via a second emulsion unit.
What is the effective infringement surface for typical dry-eye ophthalmic reformulations?
Answer: The claim set creates multiple “bands” of infringement risk:
- High-risk composition band (claim 1): correct oil-phase selection, cetalkonium chloride exclusivity as the only ammonium halide within 0.0005%–0.1% w/w, and tyloxapol/poloxamer 188 at 0.1%–1% w/w.
- Medium-risk performance band (claims 6-10): positive zeta potential, droplet size 100–500 nm, hypotonicity.
- Product-form band (claims 11, 16, 18): gel dosage form and gel preparation.
- Active and packaging band (claims 13-14, 17): cyclosporine inclusion and kit configuration.
Typical design-around levers (composition-level)
These levers map to literal claim avoidance:
- Preservative identity: omit cetalkonium chloride or add another ammonium halide (which breaks “sole ammonium halide”).
- Surfactant family: replace tyloxapol and poloxamer 188 with surfactants outside the listed set or move outside 0.1%–1% w/w.
- Oil-phase substitution: use an oil phase outside mineral oil, castor oil, and MCT.
(These are the main literal boundaries created by the claim language.)
How would claim construction likely treat “sole ammonium halide,” droplet size, and zeta potential?
Answer: The enforceable meaning will hinge on objective measurements and whether other ingredients fall within “ammonium halide” by chemical classification.
“Sole ammonium halide” (claims 1, 8, 9)
- It requires that cetalkonium chloride is the only ammonium halide present.
- If a competitor uses other quaternary ammonium halides (or other compounds that fall within the classification), they may avoid literal infringement if the classification is supported during claim construction.
Droplet size 100 to 500 nm (claim 7)
- Likely requires a measurement method (e.g., laser diffraction or similar sizing). A distribution may need to be assessed against “100 to 500 nm” depending on how courts interpret the range (mean vs D10/D50/D90). For FTO, the product’s validated specification and batch analysis become high-value evidence.
Positive zeta potential (claim 6)
- Positive zeta potential is directional. A formulation with near-zero or slightly negative values can avoid the dependent claim, even if claim 1 remains satisfied.
What is the US patent landscape around US 9,220,694 for oil-in-water ophthalmic emulsions and cyclosporine delivery?
Answer: Without the patent’s prosecution history, publication family mapping, and Orange Book/FDA listing links for the specific drug product, a complete landscape cannot be produced. This analysis is limited to the scope and enforcement surface created by the claim set you provided.
Landscape elements that must be assessed for an enforcement-ready map
Even without those bibliographic links in your prompt, the claim structure indicates where the most relevant prior art and litigation would concentrate:
- Formulation prior art on:
- O/W ophthalmic emulsions with mineral/castor/MCT oil phases
- Tyloxapol and poloxamer 188 surfactant systems
- Cetalkonium chloride preservation in emulsions and gels
- Droplet size engineering and zeta potential control for ocular tolerance
- Hypotonic formulations relative to tears
- Active delivery prior art on cyclosporine in ophthalmic vehicles, especially emulsions and gel systems.
- Excipients interaction prior art:
- tonicity agents (mannitol/glycerol)
- buffering systems used with quaternary ammonium preservatives
- Method-of-use / kit structure:
- packaging and combination approaches for dry eye treatment
Practical implication for litigation and licensing
- If US 9,220,694 is asserted against a cyclosporine ophthalmic product, the plaintiff will aim to prove claim 1 compositional matches first, then add dependent claim features (gel form, droplet size, zeta potential, hypotonicity) as secondary support.
- Defense will focus on breaking at least one of the hard gates: oil phase outside the listed set, surfactant identity outside tyloxapol/poloxamer 188 or concentration band, preservative not meeting “sole ammonium halide” requirement, or droplet size/zeta potential/hypotonicity divergence.
Claim-by-claim scope table (what must be present for infringement)
| Claim |
Additional limitation beyond claim 1 |
What must be present in the accused product |
| 1 |
O/W emulsion with specified oil phase, 0.0005%-0.1% w/w ammonium halide with cetalkonium chloride as sole ammonium halide, and 0.1%-1% w/w surfactant from tyloxapol/poloxamer 188 |
Exact component identity and concentration ranges plus O/W structure |
| 2 |
mineral oil is mixture of heavy and light mineral oil |
heavy/light mineral oil mixture rather than single mineral oil type |
| 3 |
further comprises buffering agents and/or tonicity agent |
buffer and/or tonicity present |
| 4 |
tonicity agent is mannitol |
mannitol as tonicity component |
| 5 |
tonicity agent is glycerol |
glycerol as tonicity component |
| 6 |
positive zeta potential |
measured positive zeta potential |
| 7 |
droplet size 100-500 nm |
measured droplet size distribution within range |
| 8 |
exemplar: light+heavy mineral oil + tyloxapol + poloxamer 188 + mannitol + cetalkonium chloride |
all listed features together |
| 9 |
exemplar: light+heavy mineral oil + tyloxapol + poloxamer 188 + glycerol + cetalkonium chloride |
all listed features together |
| 10 |
hypotonic vs normal tears |
osmolality below tear osmolarity comparator |
| 11 |
gel suitable for ophthalmic use |
final dosage form is gel |
| 12 |
less toxic than cetalkonium chloride solution at same wt/wt |
comparative toxicity evidence |
| 13 |
further comprises an active principle |
active present in emulsion |
| 14 |
active principle is cyclosporine |
cyclosporine present |
| 15 |
medicament comprising emulsion |
drug product uses the claimed emulsion |
| 16 |
method: prepare emulsion of claim 1 in gel form for dry eye |
manufacturing/process producing gel form |
| 17 |
kit: first emulsion claim 1 + second emulsion containing cyclosporine |
dual-emulsion kit with cyclosporine unit |
| 18 |
medicament of claim 15 in gel form |
gel dosage form plus medicament structure |
Key Takeaways
- US 9,220,694’s practical “sweet spot” is O/W ophthalmic emulsions built on mineral/castor/MCT oil phases, cetalkonium chloride as the only ammonium halide within 0.0005% to 0.1% w/w, and tyloxapol/poloxamer 188 surfactants within 0.1% to 1% w/w.
- The most enforceable core is claim 1; dependent claims add measurable formulation attributes (positive zeta potential, 100–500 nm droplet size, hypotonicity) and dosage/product configurations (gel, kit, cytosporine-containing emulsion unit).
- For FTO, the highest-risk decision points are preservative system exclusivity, surfactant family and loading band, and meeting droplet size/zeta potential/hypotonicity requirements if those dependent claims are asserted.
- For licensing or settlement, cyclosporine programs need particular attention to whether the vehicle matches the claim 1 excipient gates and whether commercial packaging uses the two-emulsion kit structure.
FAQs
-
What part of US 9,220,694 most strongly limits design-around strategies?
The combination of (a) cetalkonium chloride as the sole ammonium halide, and (b) surfactant identity restricted to tyloxapol and/or poloxamer 188 within 0.1% to 1% w/w.
-
Can a cyclosporine ophthalmic product avoid infringement by changing only the droplet size?
It may avoid dependent claim 7 if droplet size is outside 100 to 500 nm, but infringement of claim 1 can still remain if the core excipient gates are met.
-
Does using a tonicity agent automatically trigger the dependent claims on tonicity?
Not automatically. Claim 3 is triggered by having buffering agents and/or tonicity agents, but claims 4 and 5 require mannitol or glycerol specifically.
-
How does the gel dosage form affect risk?
Gel form is required for claims 11, 16, and 18. A non-gel O/W emulsion may reduce those dependent claims while still being exposed under claim 1.
-
What does the kit claim practically require for infringement exposure?
A commercial kit must include a first emulsion matching claim 1 plus a second emulsion containing cyclosporine (claim 17).
References
No sources were provided in the prompt for bibliographic details, prosecution history, assignees, family members, Orange Book status, FDA approvals, or litigation dockets. Therefore, no citations can be generated.
